Evidence map›Paper›PMID 33381316›Full record

ArticleMultiple sclerosis international2020

Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis.

Vanessa F Moreira Ferreira, Danielle Caefer, Natalie Erlich-Malona, Brian C Healy, Tanuja Chitnis, James M Stankiewicz

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Vanessa F Moreira Ferreira *Department of Neurology, Brigham and Women's Hospital, Partners MS Center, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0003-4170-6731
Danielle Caefer *University of Connecticut, Department of Physiology and Neurobiology, Storrs, CT, USA.ORCID https://orcid.org/0000-0002-3100-4085
Natalie Erlich-MalonaWarren Alpert Medical School of Brown University, Department of Neurology, Providence, RI, USA.
Brian C HealyDepartment of Neurology, Brigham and Women's Hospital, Partners MS Center, Harvard Medical School, Boston, MA, USA.
Tanuja ChitnisDepartment of Neurology, Brigham and Women's Hospital, Partners MS Center, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-9897-4422
James M StankiewiczDepartment of Neurology, Brigham and Women's Hospital, Partners MS Center, Harvard Medical School, Boston, MA, USA.ORCID https://orcid.org/0000-0002-9173-2471
Brigham and Women's Hospital · USBrown University · USUniversity of Connecticut · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo explore the safety and efficacy profile of teriflunomide in progressive multiple sclerosis.

methodsWe conducted a single-center retrospective observational analysis of a progressive multiple sclerosis population, assessing safety and efficacy in patients treated at least one year with teriflunomide or glatiramer acetate. Sustained progression of expanded disability status scale and sustained worsening of timed 25-foot walk were compared using a Cox proportional hazards model.

resultsTeriflunomide group (

conclusionIn an advanced progressive multiple sclerosis population, no substantial differences in tolerability, safety, sustained EDSS progression, or sustained T25FW worsening over time were observed between glatiramer acetate and teriflunomide-treated groups. The small sample precluded definitive determination.

Identifiers

PMID33381316
PMCPMC7759400
OpenAlexW3111501139

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.